{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:28:14Z","timestamp":1794335294549,"version":"4.9.0"},"reference-count":115,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The hemostatic system and cancer display a tight interconnection, and hemostatic imbalance frequently occurs in patients with cancer. While extensive knowledge about thrombotic risk has been generated, less is known about bleeding risk and associated risk factors. However, bleeding risk is of high significance as patients with cancer frequently receive therapeutic anticoagulation for various indications and\/or are candidates for primary thromboprophylaxis. The risk of bleeding in patients with cancer is variable and difficult to assess in clinical practice. Certain clinical settings such as hospitalization, specific underlying risk factors (e.g., tumor type), and medications (e.g., anticoagulation) can contribute to the individual bleeding risk of a patient with cancer. In addition, some dynamic factors such as platelet count or kidney function have an impact. Particularly, data on baseline risk of bleeding are lacking to allow for risk assessment in cancer patients without anticoagulation. In contrast, risk assessment models for the prediction of bleeding events in cancer patients receiving anticoagulation have been developed; however, these have yet to be validated. The recognition of the importance of bleeding risk in cancer patients is growing, leading to an increasing number of studies investigating and reporting bleeding complications. As study designs and reporting of bleeding events vary, it is challenging to offer a clear synthesis of evidence. In this narrative review, we provide an overview of currently available data about incidence, risk factors, and clinical impact of bleeding events in patients with cancer, and critically review risk assessment models for bleeding in cancer patients during anticoagulant therapy.<\/jats:p>","DOI":"10.1055\/a-2347-6507","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T23:30:21Z","timestamp":1725406221000},"page":"188-203","source":"Crossref","is-referenced-by-count":11,"title":["Bleeding Risk in Patients with Cancer"],"prefix":"10.1055","volume":"45","author":[{"given":"Cornelia","family":"Englisch","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna; Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Vladic","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna; Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna; Vienna, Austria"},{"name":"Department of Obstetrics, Gynecology and Perinatal Medicine, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-3-030-20315-3_13","article-title":"Bleeding disorders associated with cancer","volume":"179","author":"S Mantha","year":"2019","journal-title":"Cancer Treat Res"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: burden, mechanisms, and management","volume":"117","author":"C Ay","year":"2017","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"A Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"16","key":"ref4","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"N S Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"07","key":"ref5","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"D Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"G H Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"G Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"G Agnelli","year":"2012","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","article-title":"Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial","volume":"151","author":"A A Khorana","year":"2017","journal-title":"Thromb Res"},{"issue":"18","key":"ref10","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial","volume":"33","author":"U Pelzer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"08","key":"ref11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"M Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"08","key":"ref12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"A A Khorana","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1200\/JCO.2004.10.002","article-title":"Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS)","volume":"22","author":"A K Kakkar","year":"2004","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1200\/JCO.2005.03.134","article-title":"The effect of low molecular weight heparin on survival in patients with advanced malignancy","volume":"23","author":"C P Klerk","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"ref15","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.2010.31.9293","article-title":"Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer","volume":"29","author":"F F van Doormaal","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1016\/S2352-3026(20)30293-3","article-title":"Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis","volume":"7","author":"H J Sch\u00fcnemann","year":"2020","journal-title":"Lancet Haematol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.thromres.2021.09.012","article-title":"One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: results from the Cancer-VTE Registry","volume":"213","author":"Y Ohashi","year":"2022","journal-title":"Thromb Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"101768","DOI":"10.1016\/j.rpth.2023.101768","article-title":"PB0919 high rates of bleeding in unselected patients with cancer: results from a prospective cohort study","volume":"7","author":"C Englisch","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2023.05.012","article-title":"Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: a systematic review and meta-analysis","volume":"227","author":"T F Wang","year":"2023","journal-title":"Thromb Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2018.07.010","article-title":"Bleeding and venous thromboembolic events in patients with active cancer hospitalized for an acute medical illness","volume":"169","author":"M Di Nisio","year":"2018","journal-title":"Thromb Res"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jth.13606","article-title":"Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study","volume":"15","author":"B Tardy","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1253\/circj.CJ-17-1128","article-title":"Anticoagulation therapy for venous thromboembolism in the real world \u2013 from the COMMAND VTE Registry","volume":"82","author":"Y Yamashita","year":"2018","journal-title":"Circ J"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1253\/circj.CJ-19-0515","article-title":"Cancer-associated venous thromboembolism in the real world \u2013 from the COMMAND VTE Registry","volume":"83","author":"J Sakamoto","year":"2019","journal-title":"Circ J"},{"issue":"S 01","key":"ref24","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S0049-3848(16)30104-9","article-title":"Clinical course of upper extremity deep vein thrombosis in patients with or without cancer: a systematic review","volume":"140","author":"S M Bleker","year":"2016","journal-title":"Thromb Res"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ajh.25059","article-title":"Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer","volume":"93","author":"M B Streiff","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"09","key":"ref27","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3324\/haematol.13055","article-title":"Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry","volume":"93","author":"P Prandoni","year":"2008","journal-title":"Haematologica"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2023.12.016","article-title":"Cancer-associated venous thromboembolism in the direct oral anticoagulants era: insight from the COMMAND VTE Registry-2","volume":"234","author":"R Chatani","year":"2024","journal-title":"Thromb Res"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jaccao.2023.09.003","article-title":"Cancer-associated thrombosis: trends in clinical features, treatment, and outcomes from 2001 to 2020","volume":"5","author":"L Bertoletti","year":"2023","journal-title":"JACC Cardiooncol"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"A Y Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"07","key":"ref31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"A YY Lee","year":"2015","journal-title":"JAMA"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"F Posch","year":"2015","journal-title":"Thromb Res"},{"issue":"17","key":"ref33","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"ref34","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"07","key":"ref35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"ref36","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"D Schrag","year":"2023","journal-title":"JAMA"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/rth2.12359","article-title":"Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"F Moik","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study","volume":"13","author":"C W Francis","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/jth.14561","article-title":"Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study","volume":"17","author":"M Di Nisio","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jth.15599","article-title":"Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: a systematic review","volume":"20","author":"F Moik","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref41","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1253\/circj.CJ-20-0223","article-title":"risk factors for major bleeding during anticoagulation therapy in cancer-associated venous thromboembolism \u2013 from the COMMAND VTE Registry","volume":"84","author":"Y Nishimoto","year":"2020","journal-title":"Circ J"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"e00229","DOI":"10.1016\/j.heliyon.2016.e00229","article-title":"Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism","volume":"3","author":"J Trujillo-Santos","year":"2017","journal-title":"Heliyon"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jtha.2023.12.034","article-title":"Developing a machine learning model for bleeding prediction in patients with cancer-associated thrombosis receiving anticoagulation therapy","volume":"22","author":"A G Grdinic","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"25","key":"ref44","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood-2014-01-549733","article-title":"Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study","volume":"123","author":"C E Chee","year":"2014","journal-title":"Blood"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1111\/jth.14303","article-title":"Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism","volume":"16","author":"N A Zakai","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/cam4.1997","article-title":"Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: a nationwide cohort study","volume":"8","author":"M S\u00f8gaard","year":"2019","journal-title":"Cancer Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.thromres.2020.08.042","article-title":"Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism","volume":"196","author":"T L Hannevik","year":"2020","journal-title":"Thromb Res"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1486-7497","article-title":"Failure of the Ottawa score to predict the risk of recurrent venous thromboembolism in cancer patients: the prospective PREDICARE Cohort Study","volume":"122","author":"P Girard","year":"2022","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1055\/a-2145-7238","article-title":"A novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer","volume":"124","author":"A T Cohen","year":"2024","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref50","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1055\/a-1777-4006","article-title":"Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors","volume":"122","author":"R Lecumberri","year":"2022","journal-title":"Thromb Haemost"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1132156","DOI":"10.3389\/fcvm.2023.1132156","article-title":"Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events","volume":"10","author":"G Po\u00e9nou","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"S 02","key":"ref52","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0049-3848(10)70015-3","article-title":"Bleeding complications associated with anticoagulant therapy in patients with cancer","volume":"125","author":"J Trujillo-Santos","year":"2010","journal-title":"Thromb Res"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"100026","DOI":"10.1016\/j.rpth.2022.100026","article-title":"Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study","volume":"7","author":"C Ay","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0039-3400300","article-title":"Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: a study-level meta-analysis","volume":"120","author":"I Cavallari","year":"2020","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cncr.33470","article-title":"Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study","volume":"127","author":"D Pastori","year":"2021","journal-title":"Cancer"},{"issue":"19","key":"ref56","doi-asserted-by":"crossref","first-page":"e029423","DOI":"10.1161\/JAHA.123.029423","article-title":"Common cancer types and risk of stroke and bleeding in patients with nonvalvular atrial fibrillation: a population-based study in England","volume":"12","author":"A M Ajabnoor","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.amjcard.2021.11.053","article-title":"Incidence and predictors of bleeding in patients with cancer and atrial fibrillation","volume":"167","author":"S Raposeiras Roub\u00edn","year":"2022","journal-title":"Am J Cardiol"},{"issue":"11","key":"ref58","doi-asserted-by":"crossref","first-page":"101346","DOI":"10.1016\/j.cpcardiol.2022.101346","article-title":"Efficacy and safety of the non-vitamin K antagonist oral anticoagulant among patients with nonvalvular atrial fibrillation and cancer: a systematic review and network meta-analysis","volume":"47","author":"M Barbarawi","year":"2022","journal-title":"Curr Probl Cardiol"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/a-1984-7210","article-title":"Comparison of performances among four bleeding-prediction scores in elderly cancer patients with venous thromboembolism","volume":"43","author":"S Xi","year":"2023","journal-title":"Hamostaseologie"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2017.08.005","article-title":"Identifying predictors for bleeding in hospitalized cancer patients: a cohort study","volume":"158","author":"R Patell","year":"2017","journal-title":"Thromb Res"},{"issue":"08","key":"ref61","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004118","article-title":"Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis","volume":"5","author":"S Osataphan","year":"2021","journal-title":"Blood Adv"},{"issue":"02","key":"ref62","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtha.2023.10.011","article-title":"Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review","volume":"22","author":"V Iyengar","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref63","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"J I Zwicker","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"16","key":"ref64","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1182\/bloodadvances.2022008086","article-title":"ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis","volume":"6","author":"M Giustozzi","year":"2022","journal-title":"Blood Adv"},{"issue":"06","key":"ref65","doi-asserted-by":"crossref","first-page":"102172","DOI":"10.1016\/j.rpth.2023.102172","article-title":"Acute venous thromboembolism in patients with brain cancer: clinical course","volume":"7","author":"C Becattini","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"25","key":"ref66","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood-2017-02-767285","article-title":"Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin","volume":"129","author":"C Mantia","year":"2017","journal-title":"Blood"},{"issue":"02","key":"ref67","doi-asserted-by":"crossref","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"M K Gould","year":"2012","journal-title":"Chest"},{"issue":"8840","key":"ref68","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0140-6736(93)92614-Y","article-title":"Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery","volume":"341","author":"V V Kakkar","year":"1993","journal-title":"Lancet"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s13104-019-4403-0","article-title":"Incidence and risk factors for anastomotic bleeding in lower gastrointestinal surgery","volume":"12","author":"J H\u00e9bert","year":"2019","journal-title":"BMC Res Notes"},{"issue":"04","key":"ref70","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ajog.2023.10.006","article-title":"Risk of thrombosis and bleeding in gynecologic cancer surgery: systematic review and meta-analysis","volume":"230","author":"L I Lavikainen","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtha.2022.11.017","article-title":"Risk of venous thromboembolism and bleeding after major surgery for ovarian cancer: standard in-hospital versus extended duration of thromboprophylaxis","volume":"21","author":"H MG Wiegers","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref72","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/bju.16036","article-title":"Outcomes from a prospectively implemented protocol using apixaban after robot-assisted radical cystectomy","volume":"132","author":"J M Rich","year":"2023","journal-title":"BJU Int"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.urology.2021.04.054","article-title":"Direct oral anticoagulants for venous thromboembolism prophylaxis following robot-assisted radical cystectomy: a retrospective feasibility study at a single academic medical center","volume":"156","author":"R M Ortiz","year":"2021","journal-title":"Urology"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/10760296221132556","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after major gynecological cancer surgery: the VALERIA Trial : Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)","volume":"28","author":"A LM Longo de Oliveira","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"06","key":"ref75","doi-asserted-by":"crossref","first-page":"e207410","DOI":"10.1001\/jamanetworkopen.2020.7410","article-title":"Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial","volume":"3","author":"S R Guntupalli","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"08","key":"ref76","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood.2022015796","article-title":"Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer","volume":"140","author":"C Becattini","year":"2022","journal-title":"Blood"},{"issue":"05","key":"ref77","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/0003489414558109","article-title":"Postoperative hemorrhage after transoral oropharyngectomy for cancer of the lateral oropharynx","volume":"124","author":"O Laccourreye","year":"2015","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"11","key":"ref78","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamaoto.2013.5097","article-title":"Analysis of postoperative bleeding and risk factors in transoral surgery of the oropharynx","volume":"139","author":"T R Pollei","year":"2013","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"01","key":"ref79","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0885066605280884","article-title":"Mechanical complications of central venous catheters","volume":"21","author":"L A Eisen","year":"2006","journal-title":"J Intensive Care Med"},{"issue":"07","key":"ref80","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/00033197231176985","article-title":"Venous thrombosis recurrence after catheter-related upper extremity deep venous thrombosis in cancer patients: a retrospective analysis","volume":"75","author":"R Hakem","year":"2024","journal-title":"Angiology"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"880698","DOI":"10.3389\/fcvm.2022.880698","article-title":"A single center retrospective cohort study comparing different anticoagulants for the treatment of catheter-related thrombosis of the upper extremities in women with gynecologic and breast cancer","volume":"9","author":"A Porfidia","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"01","key":"ref82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12959-023-00456-9","article-title":"Efficacy and safety of rivaroxaban for the treatment of PICC-related upper extremity deep vein thrombosis in cancer patients: a retrospective study","volume":"21","author":"J Xu","year":"2023","journal-title":"Thromb J"},{"issue":"S 01","key":"ref83","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood-2022-159135","article-title":"A prospective study of apixaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients: catheter 3","volume":"140","author":"M J Kovacs","year":"2022","journal-title":"Blood"},{"issue":"04","key":"ref84","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1055\/a-1647-9896","article-title":"Extended anticoagulant treatment with full- or reduced-dose apixaban in patients with cancer-associated venous thromboembolism: rationale and design of the API-CAT Study","volume":"122","author":"I Mah\u00e9","year":"2022","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref85","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtha.2024.03.011","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial","volume":"22","author":"R D McBane II","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref86","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11239-019-01833-w","article-title":"Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study","volume":"47","author":"S Woodruff","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"07","key":"ref87","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3324\/haematol.2021.279072","article-title":"Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial","volume":"107","author":"C Becattini","year":"2022","journal-title":"Haematologica"},{"issue":"05","key":"ref88","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0038-1641150","article-title":"Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism - analysis of the CATCH Study","volume":"118","author":"R Bauersachs","year":"2018","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref89","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/jth.14007","article-title":"Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study","volume":"16","author":"P W Kamphuisen","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref90","first-page":"1849","article-title":"Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer","volume":"109","author":"R Patell","year":"2024","journal-title":"Haematologica"},{"issue":"01","key":"ref91","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/jth.15559","article-title":"Growth differentiation factor-15 for prediction of bleeding in cancer patients","volume":"20","author":"F I Mulder","year":"2022","journal-title":"J Thromb Haemost"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2023.02.003","article-title":"Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism","volume":"112","author":"M C Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2022.01.023","article-title":"Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study","volume":"165","author":"M Verso","year":"2022","journal-title":"Eur J Cancer"},{"issue":"03","key":"ref94","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1160\/TH08-02-0125","article-title":"Predicting recurrences or major bleeding in cancer patients with venous thromboembolism","volume":"100","author":"J Trujillo-Santos","year":"2008","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref95","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/j.1538-7836.2006.02082.x","article-title":"Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry","volume":"4","author":"M Monreal","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"16","key":"ref96","doi-asserted-by":"crossref","first-page":"e18744","DOI":"10.1200\/JCO.2022.40.16_suppl.e18744","article-title":"Predicting major bleeding events in anticoagulated cancer patients with venous thromboembolism using real-world data and machine learning","volume":"40","author":"A JM Mart\u00edn","year":"2022","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref97","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-0042-1758835","article-title":"Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment","volume":"123","author":"R D McBane Ii","year":"2023","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref98","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The clinical course of venous thromboembolism may differ according to cancer site","volume":"130","author":"I Mah\u00e9","year":"2017","journal-title":"Am J Med"},{"issue":"09","key":"ref99","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1007\/s00432-022-04535-8","article-title":"DOAC in the treatment of cancer-associated venous thromboembolism: a retrospective cohort study beyond the guidelines","volume":"149","author":"M Cominacini","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"ref100","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Y Je","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000314980","article-title":"Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis","volume":"79","author":"S Hapani","year":"2010","journal-title":"Oncology"},{"issue":"05","key":"ref102","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/2047487318755193","article-title":"Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients","volume":"25","author":"M Totzeck","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.2147\/OTT.S166151","article-title":"Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials","volume":"11","author":"B Xiao","year":"2018","journal-title":"OncoTargets Ther"},{"issue":"06","key":"ref104","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00228-010-0988-x","article-title":"Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials","volume":"67","author":"X F Hang","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"06","key":"ref105","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/cncr.33337","article-title":"Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin","volume":"127","author":"S H Patel","year":"2021","journal-title":"Cancer"},{"issue":"12","key":"ref106","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"A H Lipsky","year":"2015","journal-title":"Haematologica"},{"issue":"05","key":"ref107","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"J J Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.thromres.2023.10.004","article-title":"The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies","volume":"231","author":"T F Wang","year":"2023","journal-title":"Thromb Res"},{"issue":"07","key":"ref109","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s10147-019-01415-z","article-title":"Use of direct oral anti-coagulants for the treatment of venous thromboembolism in patients with advanced cancer: a prospective observational study","volume":"24","author":"T Oyakawa","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"04","key":"ref110","first-page":"135","article-title":"Dual antiplatelet therapy and cancer; balancing between ischemic and bleeding risk: a narrative review","volume":"10","author":"G Tsigkas","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"05","key":"ref111","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1055\/s-0041-1735251","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"M A de Winter","year":"2022","journal-title":"Thromb Haemost"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Z Hijazi","year":"2016","journal-title":"Lancet"},{"issue":"04","key":"ref113","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0040-1708481","article-title":"A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer","volume":"120","author":"A Abdulla","year":"2020","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref114","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1055\/a-2191-7510","article-title":"Enoxaparin for long-term therapy of venous thromboembolism in patients with cancer and renal insufficiency","volume":"124","author":"P Siguenza","year":"2024","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref115","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"S Kaatz","year":"2015","journal-title":"J Thromb Haemost"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2347-6507.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T23:14:12Z","timestamp":1746659652000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2347-6507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":115,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,5,4]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2347-6507","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]}}}